Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on,
parallel-group study to evaluate the effect of rasagiline on cognitive function in adults
with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
Phase:
Phase 4
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.